** Shares of drug developer NeuroSense Therapeutics' NRSN.O rise 9% to $1.20 during early trading

** Co says has received clearance from the U.S. FDA to begin late-stage clinical trial of its experimental drug, PrimeC, for amyotrophic lateral sclerosis or ALS

** Amyotrophic lateral sclerosis is a fatal neurodegenerative disease

** The late-stage trial will enroll 300 patients in U.S. and EU; aims to confirm prior mid-stage results - NRSN

** Co's PrimeC combines two approved drugs to slow ALS progression by targeting inflammation and RNA regulation, co says

** Including session's move, stock down ~1.7% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))